SANET-ep and SANET-p
In the SANET trials, a Chinese anti-angiogenic pill slowed both gut and pancreatic neuroendocrine tumours, but its US application was refused.
SANET-ep PFS 9.2 vs 3.8 months (HR 0.33); SANET-p PFS 10.9 vs 3.7 months (HR 0.49). Approved in China (2020-21); FDA complete response letter (2022) requiring a multiregional trial.
- Median 9.2 vs 3.8 months with Surufatinib compared with Placebo; about 5.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 67 percent lower chance of the event at any given time (hazard ratio 0.33).
- Median 10.9 vs 3.7 months with Surufatinib compared with Placebo; about 7.2 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 51 percent lower chance of the event at any given time (hazard ratio 0.49).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Progressive extra-pancreatic (n=198) and pancreatic (n=172) NETs: surufatinib vs placebo (China). People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
369 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (SANET-ep)primary | Surufatinib | — | 9.2 months | 0.33 | — | — |
| Placebo | — | 3.8 months | ||||
| Progression-free survival (SANET-p)primary | Surufatinib | — | 10.9 months | 0.49 | — | — |
| Placebo | — | 3.7 months |
Pages like this
not linked directly; found by shared links- TrialMAPS
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- TrialSELECT
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- PersonEmily K. Bergsland
Shares VEGF / VEGFR, Neuroendocrine tumours.
- ProductPazopanib
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- PersonJudah Folkman
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- ProductBevacizumab (glioblastoma use)
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- TermLigand
Shares Anti-angiogenic therapy, VEGF / VEGFR.
- ProductAxitinib
Shares Anti-angiogenic therapy, VEGF / VEGFR.